Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: Role of natriuretic peptides and angiotensin II

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 1, 1998, Pages 116-125

  Rademaker, M T ^a   Charles, C J ^a   Espiner, E A ^a   Nicholls, M G ^a   Richards, A M ^a   Kosoglou, T ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Angiotensin II; Cyclic GMP; Hemodynamics; Natriuresis; Natriuretic peptides; Ventricular pacing

Indexed keywords

ANGIOTENSIN; CAPTOPRIL; N (1 CARBOXY 2 PHENYLETHYL)PHENYLALANYL BETA ALANINE; NATRIURETIC FACTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIURESIS; ENZYME INHIBITION; HEART FAILURE; INHIBITION KINETICS; MEAN ARTERIAL PRESSURE; NATRIURESIS; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; SHEEP;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; MYOCARDIUM; NEPRILYSIN; PEPTIDYL-DIPEPTIDASE A; SHEEP; TIME FACTORS; VENTRICULAR FUNCTION;

EID: 0031975483     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199801000-00017     Document Type: Article

References (40)

1. Svanegaard J, Johansen JB, Thayssen P, Haghfelt T. Neurohormonal systems during progression of heart failure: a review. Cardiology 1993;83:21-9.
2. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402-12.
3. Drexler H, Hirth C, Stasch HP, Lu W, Neuser D, Just H. Vasodilatory action of atrial natriuretic factor in a rat model of chronic heart failure as determined by monoclonal ANF antibody. Circ Res 1990;66:1371-80.
4. Herrmann HC, Palacios IF, Dec GW, Scheer JM, Fifer MA. Effects of atrial natriuretic factor on coronary hemodynamic and myocardial energetics in patients with heart failure. Am Heart J 1988; 115:1232-8.
5. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide in patients with congestive heart failure. Circulation 1991;84:1581-8.
6. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-35.
7. Pierpont GL, Francis GS, Cohn JN. Effect of captopril on renal function in patients with congestive heart failure. N Engl J Med 1981;46:522-7.
8. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 1993;291:83-8.
9. Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM, Kosoglou T. Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin Sci 1996;91:283-91.
10. Fitzpatrick MA, Rademaker MT, Charles CJ, et al. Acute hemodynamic, hormonal and renal effects of neutral endopeptidase inhibition in ovine heart failure. J Cardiovasc Pharmacol 1992;19:635-40.
11. Seymour AA, Asaad MM, Lanoce VM, Fennell SA, Cheung HS, Rogers WL. Inhibition of neutral endopeptidase 3.24.11 in conscious dogs with pacing induced heart failure. Cardiovasc Res 1993;27:1015-23.
12. Trippodo NC, Fox M, Natarajan V, Panchal BC, Dorso CR, Assad MM. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme in cardiomyopathic hamsters with compensated heart failure. J Pharmacol Exp Ther 1993;267:108-16.
13. Trippodo NC, Robl JA, Assad MM, et al. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin- converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther 1995;275(2):745-52.
14. Seymour AA, Asaad MM, Lanoce VM, Langebacher KM, Fennell SA, Rogers WL. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 1993;266(2):872-83.
15. Margulies KB, Perrella MA, McKinley LJ, Burnett JC. Angiotensin inhibition potentiates the renal response to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest 1991;88:1636-42.
16. Shimamori Y, Watanabe Y, Fujimoto Y. Specificity of a membrane bound neutral endopeptidase from rat kidney. Chem Pharmacol Bull 1986;34:275-80.
17. Richards AM, Wittert GA, Crozier IG, et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension - evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993;11(4):407-16.
18. Norman JA, Little D. Bolger M, di Donato G. Degradation of brain natriuretic peptide by neutral endopeptidase: species specific sites of proteolysis determined by mass spectrometry. Biochem Biophys Res Commun 1991;175:22-30.
19. Vanneste Y, Pauwels S, Lambotte L, Deschodt-Lanckman M. In vivo metabolism of brain natriuretic peptide in the rat involves endopeptidase 24.11 and angiotensin converting enzyme. Biochem Biophys Res Commun 1990;173(1):265-71.
20. Fitzpatrick MA, Nicholls MG, Espiner EA, et al. Neurohumoral changes during the onset and offset of ovine heart failure: role of ANP. Am J Physiol 1989;256:H1052-9.
21. Fitzpatrick MA, Rademaker MT, CFrampton CM, et al. Hemodynamic and hormonal effects of renin inhibition in ovine heart failure. Am J Physiol 1990;258:H1625-31.
22. Charles CJ, Espiner EA, Cameron VA, Richards AM. Hemodynamic, renal, and endocrine actions of ANF in sheep: effect of 24-h, low-dose infusions. Am J Physiol 1990;258:R1279-85.
23. Yandle TG, Aitken GD, Fisher SF, Rademaker MT, Espiner EA, Nicholls MG. Ovine brain natriuretic peptide: identity measurement and regulation [Abstract]. J Hypertens 1994;12:50S.
24. Northridge DB, Jardine AG, Findlay IN, Archibald M, Dilly SG, Dargie HJ. Inhibition of the metabolism of atrial natriuretic factor causes diuresis and natriuresis in chronic heart failure. Am J Hypertens 1990;3:682-7.
25. Lang CC, Motwani JG, Coutie WJR, Struthers AD. Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism. Clin Sci 1992;82:619-23.
26. Aitken GD, George P, Espiner EA. Characterisation of ovine natriuretic peptide genomic DNA sequences [Abstract]. J Hypertens 1994;12(suppl 3):174.
27. Lang CC, Motwani JG, Rahman AR, Coutie WJ, Struthers AD. Effect of angiotensin-converting enzyme on plasma natriuretic peptide levels in patients with heart failure. Clin Sci 1992;83:143-7.
28. Lang CC, Choy AMJ, Henderson IS, Coutie WJR, Struthers AD. Effect of haemodialysis on plasma levels of brain natriuretic peptide in patients with chronic renal failure. Clin Sci 1992;82:127-31.
29. Obana K, Naruse M, Naruse K, et al. Synthetic rat atrial natriuretic factor inhibits in vitro and in vivo renin secretion in rats. Endocrinology 1985;117:1282-4.
30. Pinto YM, De Smet BGJL, Van Gilst WH, et al. Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology. Cardiovasc Res 1993;27:1933-8.
31. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. J Clin Invest 1990;86:1913-20.
32. Fujisaki H, Ito H, Hirata Y, et al. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 expression. J Clin Invest 1995;96:1059-65.
33. Monopoli A, Ongini E, Cigola E, Olivetti G. The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1992;20:496-504.
34. Bralet J, Marie C, Mossiat C, Lecomte J, Gros C, Schwartz J. Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction: comparison with captopril. J Pharmacol Exp Ther 1994;270(1):8-14.
35. Maxwell AJ, Husseini WK, Piedimonte G, Hoffman JIE. Effects of inhibiting endopeptidase and kininase II on coronary and systemic hemodynamics in rats. Am J Physiol 1995;269(38):H1016-29.
36. Fitzpatrick MA, Rademaker MT, Charles CJ, et al. Comparison of the effect of renin inhibition and angiotensin-converting enzyme inhibition in ovine heart failure. J Cardiovasc Pharmacol 1992; 19:169-75.
37. Manthey J, Osterziel J, Rohrig N, et al. Ramipril and captopril in patients with heart failure: effects on hemodynamics and vasoconstrictor systems. Am J Cardiol 1987;59:171D-5D.
38. Seymour AA, Abboa-Offei BE, Smith PL, Mathers PD, Asaad MM, Rogers WL. Potentiation of natriuretic peptides by neutral endopeptidase inhibitors. Clin Exp Pharmacol Physiol 1995;22:63-9.
39. Gonzalez W, Beslot F, Laboulandine I, Fournie-Zaluski M-C, Roques B-P, Michel J-P. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction. J Pharmacol Exp Ther 1996; 278:573-81.
40. Marin-Grez M, Fleming JT, Steinhausen M. Atrial natriuretic peptide causes pre-glomerular vasodilation and post-glomerular vasoconstriction in rat kidney. Nature 1986;324;473-6.